Get the Stockscreener App
25.46
7.56%
1.79
Pulse Biosciences Inc stock is traded at $25.46, with a volume of 516.35K.
It is up +7.56% in the last 24 hours and up +78.67% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
See More
Previous Close:
$23.67
Open:
$23.55
24h Volume:
516.35K
Relative Volume:
1.91
Market Cap:
$1.73B
Revenue:
$-9,000
Net Income/Loss:
$-68.03M
P/E Ratio:
-24.25
EPS:
-1.05
Net Cash Flow:
$-44.76M
1W Performance:
+0.83%
1M Performance:
+78.67%
6M Performance:
+62.37%
1Y Performance:
+16.31%
1-Day Range:
$23.33
$25.80
1-Week Range:
$22.67
$25.80
52-Week Range:
$12.56
$26.30
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
25.46 | 1.60B | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
500.76 | 175.20B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
182.68 | 50.46B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
82.29 | 39.65B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
47.71 | 38.41B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
258.91 | 37.27B | 5.40B | 1.49B | 1.78B | 10.12 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Mizuho | Outperform |
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
A Glimpse of Pulse Biosciences's Earnings Potential - Benzinga
Pulse Biosciences CCO Danahy sells $1.41 million in stock By Investing.com - Investing.com South Africa
Pulse Biosciences CCO Danahy sells $1.41 million in stock - Investing.com
Pulse Biosciences, Inc (PLSE) Stock Analysis: Exploring a Potential 12.99% Upside in the Healthcare Sector - DirectorsTalk Interviews
Will Pulse Biosciences Inc. stock continue dividend increases2025 Market WrapUp & Long Hold Capital Preservation Tips - mfd.ru
Is Pulse Biosciences Inc. affected by consumer sentimentTreasury Yields & Community Consensus Stock Picks - mfd.ru
Can Pulse Biosciences Inc. sustain its profitability2025 Technical Patterns & Verified Technical Trade Signals - mfd.ru
Pulse Biosciences (NASDAQ:PLSE) Shares Down 9.2% Following Insider Selling - MarketBeat
PLSE shares positive first-in-human nPulse cardiac catheter data - MSN
Pulse Biosciences (PLSE) to Release Earnings on Thursday - MarketBeat
Pulse Biosciences (NASDAQ:PLSE) Insider Kevin Patrick Danahy Sells 20,000 Shares - MarketBeat
Kevin Patrick Danahy Sells 20,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock - MarketBeat
Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 7.5%Here's What Happened - MarketBeat
Is Pulse Biosciences Inc. stock a good pick for beginners2025 Pullback Review & Consistent Income Trade Recommendations - mfd.ru
Pulse Biosciences (PLSE) Is Up 70.4% After Strong First-in-Human nPulse AF Data Release – Has The Bull Case Changed? - Sahm
Why Pulse Biosciences Inc. (6L8) stock could break out in 2025Trade Entry Report & High Win Rate Trade Alerts - mfd.ru
Pulse Biosciences, Inc. (PLSE) Stock Analysis: Riding a Wave of Innovation with a 7.39% Upside Potential - DirectorsTalk Interviews
Pulse Biosciences (NASDAQ:PLSE) Hits New 52-Week HighWhat's Next? - MarketBeat
Pulse Biosciences stock hits 52-week high at 22.76 USD By Investing.com - Investing.com South Africa
Pulse Biosciences stock hits 52-week high at 22.76 USD - Investing.com Nigeria
Pulse Biosciences (NASDAQ:PLSE) Sees Strong Trading VolumeShould You Buy? - MarketBeat
PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data - TradingView
Abbott details Volt, TactiFlex data; Pulse Biosciences’ results shine - MedTech Dive
Pulse Biosciences Highlights Strong AF Outcomes From NPulse Feasibility Study - Nasdaq
A Look At Pulse Biosciences (PLSE) Valuation After Its Recent Share Price Surge - Sahm
Precision Trading with Pulse Biosciences Inc (PLSE) Risk Zones - Stock Traders Daily
We're Not Very Worried About Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate - Yahoo Finance
Pulse Biosciences Stock Pre-Market (+5.5%): Searching for a Catalyst - Trefis
Pulse Biosciences Heart Device Data Fuels Stock Surge - Benzinga
Top Midday Gainers - marketscreener.com
Pulse Biosciences (NASDAQ:PLSE) Shares Gap UpHere's What Happened - MarketBeat
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Pulse Biosciences stock rises after positive cardiac catheter study data By Investing.com - Investing.com Canada
Pulse Biosciences, Inc. Announces nPulse Cardiac Catheter Study Results - TradingView
Pulse Biosciences Shares Rise as Cardiac Catheter Feasibility Study Shows Successful Atrial Fibrillation Treatment - marketscreener.com
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardia - The National Law Review
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium - MEXC
Pulse Biosciences Achieves Success in Cardiac Catheter Study - Intellectia AI
Pulse Biosciences (PLSE) Reports Promising Clinical Data from Ca - GuruFocus
Pulse Biosciences Presents Late-Breaking Data from nPulse Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium - Investing News Network
AF heart study in 150 patients reports 96% success at 1 year - Stock Titan
Maria Sainz Joins Pulse Biosciences Board of Directors - Medical Product Outsourcing
Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026 - The Joplin Globe
Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium - BioSpace
Analyst Calls: How does TELA correlate with NasdaqPortfolio Update Summary & Stock Market Timing Techniques - baoquankhu1.vn
Pulse Biosciences' nPulse Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium - Investing News Network
Mizuho Initiates Coverage on Pulse Biosciences (NASDAQ:PLSE) - Defense World
Mizuho Securities Initiates Coverage on Pulse Biosciences With Outperform Rating - marketscreener.com
Mizuho initiates Pulse Biosciences stock with Outperform rating, $25 target By Investing.com - Investing.com Canada
Does Pulse Biosciences Inc. have strong fundamentalsJuly 2025 Volume & Momentum Based Trading Ideas - mfd.ru
Technical Reactions to PLSE Trends in Macro Strategies - Stock Traders Daily
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):